ASH Annual Meeting and Exposition | Conference

Ibrutinib Plus Rituximab Confers Superior PFS to FCR in Previously Untreated CLL

December 13th 2021

The results also demonstrated no significant difference in overall survival benefit between the treatment groups. However, almost all patients switched from FCR to ibrutinib or another regimen after disease relapse.

Cilta-Cel Provides Superior Option Vs Standard Regimens in Triple-Class Exposed Multiple Myeloma

December 13th 2021

Comparative data from the phase 1 CARTITUDE-1 trial and the real-world LocoMMotion study demonstrated that ciltacabtagene autoleucel bested standard options for patients with triple-class exposed multiple myeloma.

Venetoclax/Selinexor Combo Shows Efficacy in Relapsed/Refractory Multiple Myeloma With t(11;14)

December 13th 2021

Selinexor combined with venetoclax demonstrated efficacy and tolerability in heavily pretreated relapsed/refractory multiple myeloma cell lines with t(11;14), according to small study results that were presented during the 2021 ASH Annual Meeting.

First-Line Itolizumab Associated With High Rates of Clinical Response, Tolerability in Acute GVHD

December 13th 2021

The first-in-class monoclonal antibody treatment for acute graft-versus-host disease had durable responses and tolerability for patients.

Glofitamab Monotherapy, Plus Obinutuzumab Show High Responses in Relapsed/Refractory Follicular Lymphoma

December 13th 2021

Glofitamab, an investigational CD20xCD3 bispecific antibody, induced high response rates as monotherapy or in combination with obinutuzumab in patients with multiple relapsed or refractory follicular lymphoma.

Liso-Cel Induces Durable Responses in Relapsed/Refractory B-Cell Lymphomas

December 13th 2021

Treatment with lisocabtagene maraleucel demonstrated durable responses in patients with relapsed/refractory large B-cell lymphomas.

Treatment Selection Could Be Informed by Cost and Time Spent on Managing Toxicity in CLL

December 13th 2021

Cost and personal time spent on managing adverse effects for treatment with ibrutinib, acalabrutinib, or venetoclax could inform decision-making strategies for treatment selection in patients with chronic lymphocytic leukemia.

Naratuximab Emtansine Plus Rituximab Serves Unmet Need in Relapsed/Refractory DLBCL Treatment

December 13th 2021

Naratuximab emtansine plus rituximab had promising response rates while also improving patient well-being when used to treat diffuse relapsed/refractory large B-cell lymphoma and other non-Hodgkin B-cell lymphomas.

Time-Limited Ublituximab/Umbralisib Plus Ibrutinib Achieves 77% uMRD Rate in CLL

December 13th 2021

The addition of ublituximab and umbralisib to ibrutinib produced deep remissions with favorable tolerability in patients with chronic lymphocytic leukemia who previously received ibrutinib and still had detectable minimal residual disease.

Axi-Cel Demonstrates 60% EFS Improvement in Second-Line Relapsed/Refractory LBCL

December 13th 2021

Axicabtagene ciloleucel led to a 60% improvement in event-free survival compared with standard-of-care chemotherapy as second-line treatment for patients with relapsed/refractory large B-cell lymphoma.

Cilta-cel Shows Greater Clinical Benefit Than SOC in Triple-Class Relapsed/Refractory Myeloma

December 12th 2021

Ciltacabtagene autoleucel demonstrated a significant advantage over physician’s choice of treatment with regard to overall survival, progression-free survival, time to next treatment, and overall response rate, underscoring its potential for use in patients with triple-class relapsed/refractory multiple myeloma.

Dr. Frey on the Utility of CART22-65s with huCART19 in Relapsed/Refractory ALL

December 12th 2021

Noelle V. Frey, MD, MSCE, discusses the results of a study evaluating the utility of co-administered CART22-65s and huCART19 in relapsed/refractory acute lymphoblastic leukemia that were presented at the 2021 ASH Annual Meeting & Exposition.

Dr. Locke on the Results of the ZUMA-7 Trial in Relapsed/Refractory Large B-Cell Lymphoma

December 12th 2021

Frederick Locke, MD, discusses the results of the phase 3 ZUMA-7 trial in patients with large B-cell lymphoma that were presented at the 2021 ASH Annual Meeting & Exposition.

Daratumumab/IRd Quadruplet Is Safe and Effective as Induction, Consolidation for Standard-Risk Myeloma

December 12th 2021

Extended induction and consolidation therapy with daratumumab plus ixazomib, lenalidomide, and dexamethasone led to deepening rates of minimal residual disease for patients with standard-risk, transplant-eligible newly diagnosed multiple myeloma.

IPSS, JAK2 Status May Identify Risk for Thrombosis in Primary Myelofibrosis

December 12th 2021

The use of the International Prognostic Scoring System score and JAK2 mutation status may identify patients at risk for major arterial and venous thrombosis in primary myelofibrosis, and suggests appropriate anti-thrombotic prophylaxis.

MRD-Guided Therapy Could Inform Treatment-Free Surveillance in Newly Diagnosed Multiple Myeloma

December 12th 2021

Minimal residual disease, assessed through next-generation sequencing was found to inform treatment selection and duration with daratumumab plus carfilzomib, lenalidomide, and dexamethasone following autologous transplant in patients with newly diagnosed multiple myeloma.

Axi-Cel Improves QoL in Second-Line Treatment of LBCL

December 12th 2021

Axicabtagene ciloleucel, an autologous anti-CD19 CAR T-cell therapy, resulted in clinically meaningful improvement in quality of life at day 100 compared with standard of care as a second-line treatment of patients with relapsed/refractory large B-cell lymphoma.

Weekly Selinexor/Bortezomib/Dexamethasone Combo Demonstrates Favorable Efficacy and Safety in High-Risk Multiple Myeloma

December 12th 2021

Weekly selinexor plus bortezomib and dexamethasone represents a favorable option for patients with multiple myeloma and any cytogenetic profile, based on comparable objective responses rates and progression-free survival results from 2 clinical trials.

Chemotherapy Plus Eryaspase Demonstrates Efficacy in ALL With Risk for Hypersensitivity Reactions

December 12th 2021

The addition of eryaspase to chemotherapy demonstrated biological efficacy and tolerability in patients with acute lymphoblastic leukemia who are at risk of developing hypersensitivity reactions to Escherichia coli–derived pegylated asparaginase.

Tisagenlecleucel Continues to Show Favorable Real-World Efficacy and Safety in R/R B-Cell Non-Hodgkin Lymphomas

December 12th 2021

Tisagenlecleucel demonstrated encouraging real-world efficacy and a favorable safety profile that was consistent with findings from the pivotal phase 2 JULIET trial in patients with relapsed/refractory diffuse large B-cell lymphoma or high-grade B-cell lymphoma.